Post-marketing Study Assessing the Serious Cardiovascular Events Among Osteoporotic Patients Initiating Romosozumab in Japan Using the Medical Information Database Network (MID-NET) (20190206)

23/09/2024
04/06/2026
EU PAS number:
EUPAS1000000308
Study
Ongoing
Study summary
No information provided.
Study identification

EU PAS number

EUPAS1000000308

Study ID

1000000308

Official title and acronym

Post-marketing Study Assessing the Serious Cardiovascular Events Among Osteoporotic Patients Initiating Romosozumab in Japan Using the Medical Information Database Network (MID-NET) (20190206)

DARWIN EU® study

No

Study countries

Japan

Study description

No information provided.

Study status

Ongoing

Contact details

Global Development Leader Amgen Inc. medinfo@amgen.com

Study contact

Global Development Leader Amgen Inc.

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Date of final study report

Planned:
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only